AlzeCure Pharma AB

As of June 30, 2026, AlzeCure Pharma AB carries a market capitalization of 444.72M, placing it among publicly traded companies globally. Its enterprise value stands at 433.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AlzeCure Pharma AB's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, AlzeCure Pharma AB has 114.91M shares outstanding.

As of June 30, 2026, AlzeCure Pharma AB trades at a trailing price-to-earnings ratio of 15.86. The price-to-sales ratio is 5.01, and the price-to-book ratio stands at 4.87.

As of June 30, 2026, AlzeCure Pharma AB trades at an EV/EBITDA multiple of 13.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 433.24M versus a market cap of 444.72M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AlzeCure Pharma AB maintains a current ratio of 4.11, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.20, indicating elevated leverage, while an interest coverage ratio of 131.90 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AlzeCure Pharma AB posted a return on equity (ROE) of 62.85, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 44.28, measuring how efficiently the asset base is converted into earnings. The company generates approximately 9.50M in revenue per employee across its workforce of 10.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, AlzeCure Pharma AB recorded an income tax benefit of -10,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 30.71M, leaving 30.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, AlzeCure Pharma AB's stock has gained approximately 217.01% over the past 52 weeks. The 50-day moving average sits at 7.32, while the 200-day moving average is 3.92.

Over the twelve months ended June 30, 2026, AlzeCure Pharma AB generated 97.33M in revenue and converted that into 30.72M in net income, yielding earnings per share of 0.24. EBITDA reached 31.66M, while operating income came in at 30.44M.

As of June 30, 2026, AlzeCure Pharma AB holds 13.49M in cash and equivalents against 2.01M in total debt, resulting in a net debt position of -13.49M. Total book value stands at 91.41M, with working capital of 89.91M providing operational flexibility.

AlzeCure Pharma AB produced -52.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -52.48M - equivalent to -0.42 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 31.28 and net profit margin of 31.56 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.01, meaning AlzeCure Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AlzeCure Pharma AB's most recent stock split took place on June 11, 2026 with a 945:1079 split ratio.

As of June 30, 2026, AlzeCure Pharma AB has an Altman Z-Score of 6.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.